Efficacy and safety of cell-based regenerative therapies for fistula-related diseases: An umbrella review of systematic reviews

Figure 1  Flow diagram.

Figure 2 Evidence bubble plot of comparative effects of regenerative therapies vs control. MSC: Mesenchymal stem cell; AD-MSC: Adipose-derived mesenchymal stem cell; BM-MSC: Bone marrow-derived mesenchymal stem cell; PF: Perianal fistulas; FCD: Fistulizing Crohn’s disease; PDAI: Perianal disease activity index; AE: Adverse event; GRADE: Grading of Recommendations, Assessment, Development and Evaluation; W: week(s).

Figure 3 Forest plots of pooled remission outcomes and pooled clinical and/or radiological healing outcomes from single-arm meta-analyses of regenerative therapies, and pooled adverse events associated with regenerative therapies. A: Forest plots of pooled remission outcomes from single-arm meta-analyses of regenerative therapies; B: Forest plots of pooled clin/rad healing outcomes from single-arm meta-analyses of regenerative therapies; C: Forest plots of pooled adverse events associated with regenerative therapies. CI: Confidence interval; MSC: Mesenchymal stem cell; AD-MSC: Adipose-derived mesenchymal stem cell; BM-MSC: Bone marrow-derived mesenchymal stem cell; PRP: Platelet-rich plasma; CD: Crohn’s disease; HU-MSC: Human umbilical cord mesenchymal stem cell; HSC: Hematopoietic stem cell; SVF: Stromal vascular fraction; ASC: Autologous stem cell; AE: Adverse event; GRADE: Grading of Recommendations, Assessment, Development and Evaluation; W: week(s).